EA5182: Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Click on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email [email protected] or call 312-355-5112.

EA5182: Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Sushma Jonna, MD